Physician profile
Crawford Strunk
NPI 1770533291
$51,779.08
in general payments reported to CMS, 2019-2025
14 companies · $2,006 in 2025
The $2,006 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $5,631 · 2021: $13K · 2022: $18K · 2023: $89.99 · 2024: $269 · 2025: $2,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,550 · Food and Beverage: $798 · Travel and Lodging: $16.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,550.00 |
| Food and Beverage | $798.16 |
| Travel and Lodging | $16.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $20,426.73 | 2020-2022 | |
| Duchesnay USA Incorporated | $15,437.50 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $12,965.25 | 2019-2021 | |
| Pfizer INC. | $1,647.20 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $554.17 | 2023-2025 | Pyrukynd |
| Chiesi USA, INC. | $196.38 | 2021-2022 | |
| Emmaus Medical, INC. | $157.27 | 2019-2022 | |
| Amgen INC. | $152.69 | 2019-2020 | |
| Novo Nordisk INC | $121.58 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $42.00 | 2025 | |
| Genentech USA, INC. | $24.33 | 2020 | |
| Kedrion Biopharma INC. | $22.00 | 2019 | |
| Grifols USA, LLC | $19.72 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crawford Strunk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.